z-logo
open-access-imgOpen Access
POINT-COUNTERPOINT: Oncology Congress Debate: Should Initial Chemotherapy for Ovarian Cancer Include Bevacizumab? Yes: Bradley Monk, MD; No: William P. McGuire, MD
Author(s) -
Rabiya S. Tuma
Publication year - 2011
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000393680.30811.3c
Subject(s) - counterpoint , bevacizumab , oncology , medicine , ovarian cancer , chemotherapy , cancer , psychology , pedagogy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom